GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mereo BioPharma Group PLC (NAS:MREO) » Definitions » 3-Year Revenue Growth Rate

Mereo BioPharma Group (Mereo BioPharma Group) 3-Year Revenue Growth Rate : 0.00% (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Mereo BioPharma Group 3-Year Revenue Growth Rate?

Mereo BioPharma Group's Revenue per Share for the six months ended in Dec. 2023 was $0.01.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.


Competitive Comparison of Mereo BioPharma Group's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, Mereo BioPharma Group's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mereo BioPharma Group's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mereo BioPharma Group's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Mereo BioPharma Group's 3-Year Revenue Growth Rate falls into.



Mereo BioPharma Group 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.


Mereo BioPharma Group  (NAS:MREO) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.


Mereo BioPharma Group 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Mereo BioPharma Group's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Mereo BioPharma Group (Mereo BioPharma Group) Business Description

Traded in Other Exchanges
Address
One Cavendish Place, 4th Floor, London, GBR, W1G 0QF
Mereo BioPharma Group PLC is a multi-asset, clinical-stage biopharmaceutical company. It is focused on the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. Its oncology product candidate is etigilimab, for patients with solid tumors. Some of the other products in the pipeline are setrusumab, alvelestat, leflutrozole, navicixizumab, and acumapimod.

Mereo BioPharma Group (Mereo BioPharma Group) Headlines

From GuruFocus

Mereo BioPharma to Host Alvelestat R&D Update Call on October 31, 2022

By Value_Insider Value_Insider 10-24-2022